Article thumbnail

IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection

By Chun-Yen Lin, Ji-Yih Chen, Tsung-Nan Lin, Wen-Juei Jeng, Chien-Hao Huang, Chang-Wen Huang, Su-Wei Chang and I-Shyan Sheen
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3068186
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). [Peginterferon alfa2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
  2. (2007). A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
  3. (2006). A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
  4. (2006). Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients.
  5. (2010). Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in
  6. (2009). Diagnosis, management, and treatment of hepatitis C: An update.
  7. (2003). Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
  8. (2006). Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
  9. (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.
  10. (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
  11. (2009). Genome-wide association of IL28B with response to pegylated interferon[alpha] and ribavirin therapy for chronic hepatitis C.
  12. (2009). Genomics: Hepatitis C virus gets personal.
  13. (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.
  14. (2010). Interleukin28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
  15. (2008). Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
  16. (2005). Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
  17. (2009). Peginterferon alfa2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
  18. (2007). Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
  19. (2005). Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
  20. (2007). Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
  21. (2008). Pegylated interferonalpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
  22. (2008). Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
  23. (2009). Treatment of chronic hepatitis C in Asia: when East meets West.
  24. (2004). Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.